TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway

Figure 1

TAK-875 improved PA or LPS-induced β-cell damage in a dose-dependent manner. (a–c) TAK-875 improves PA-induced apoptosis (the white arrow indicates the apoptotic cells) (a), insulin secretion disorder (b), and TLR4 and NF-κB subunit P65 expression (c). (d–f) TAK-875 improves LPS-induced apoptosis (d), insulin secretion disorder (e), and TLR4 and NF-κB subunit P65 expression (f). ^a vs. NC group (without PA and TAK-875), ^b vs. 100 nmol/L TAK-875 group, ^c vs. 0.5 mmol/L PA group, ^d vs. 0.5 mmol/L PA+25 nmol/L TAK-875 group, and ^e vs. 0.5 mmol/L PA+50 nmol/L TAK-875 group.

(a)

(b)

(c)

(d)

(e)

(f)